BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 3.7% After Insider Selling

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares fell 3.7% on Tuesday after an insider sold shares in the company. The stock traded as low as $6.00 and last traded at $6.01. 600,286 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 3,433,885 shares. The stock had previously closed at $6.24.

Specifically, CFO Anthony Doyle acquired 36,300 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were purchased at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the completion of the purchase, the chief financial officer now owns 266,744 shares in the company, valued at $1,485,764.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Anthony Doyle bought 36,300 shares of BioCryst Pharmaceuticals stock in a transaction on Tuesday, May 14th. The stock was acquired at an average cost of $5.57 per share, for a total transaction of $202,191.00. Following the completion of the acquisition, the chief financial officer now owns 266,744 shares of the company’s stock, valued at approximately $1,485,764.08. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Machelle Sanders sold 4,689 shares of the firm’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $6.00, for a total transaction of $28,134.00. Following the completion of the sale, the director now owns 27,742 shares in the company, valued at $166,452. The disclosure for this sale can be found here. In the last ninety days, insiders bought 103,601 shares of company stock worth $596,338. 4.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BCRX. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. Needham & Company LLC restated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. Finally, JMP Securities upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.00.

BioCryst Pharmaceuticals Stock Performance

The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -5.61 and a beta of 1.88. The business’s 50 day moving average price is $5.57 and its 200 day moving average price is $5.61.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. The firm had revenue of $92.80 million for the quarter, compared to analyst estimates of $85.62 million. The firm’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.28) EPS. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Tidal Investments LLC acquired a new position in BioCryst Pharmaceuticals during the first quarter worth $282,000. Redwood Investment Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at approximately $621,000. Jacobs Levy Equity Management Inc. raised its stake in BioCryst Pharmaceuticals by 62.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 156,119 shares of the biotechnology company’s stock valued at $793,000 after purchasing an additional 59,722 shares during the last quarter. Kynam Capital Management LP lifted its holdings in BioCryst Pharmaceuticals by 41.9% in the 1st quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after purchasing an additional 1,927,491 shares in the last quarter. Finally, Sarissa Capital Management LP boosted its stake in BioCryst Pharmaceuticals by 9.4% during the 1st quarter. Sarissa Capital Management LP now owns 1,094,168 shares of the biotechnology company’s stock worth $5,558,000 after purchasing an additional 94,168 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.